Silence Therapeutics plc Share Price London S.E.
Stocks
GB0008433350
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| Market Cap | 43Cr 57Cr 51Cr 48Cr 82Cr 5.55TCr 82Cr 573.3Cr 224.23Cr 2.82TCr 215.21Cr 210.54Cr 9.07TCr | P/E 2026 * |
-17.9x | P/E 2027 * | -14.4x |
|---|---|---|---|---|---|
| Enterprise Value | 30Cr 40Cr 35Cr 33Cr 57Cr 3.85TCr 57Cr 397.39Cr 155.43Cr 1.96TCr 149.18Cr 145.94Cr 6.29TCr | EV / Sales 2026 * |
932x | EV / Sales 2027 * | 346x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 01/12/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 01/02/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 21/06/2018 |
Iain Ross
CHM | Chairman | 72 | 01/01/2004 |
Tim McInerney
BRD | Director/Board Member | 65 | 05/05/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.19% | -3.19% | +44.60% | +87.98% | 7.47TCr | |
| -15.86% | -16.16% | +2.68% | +50.90% | 5.87TCr | |
| -2.39% | -2.05% | +4.29% | +31.33% | 4.84TCr | |
| -6.35% | -8.63% | +293.39% | +651.28% | 4.31TCr | |
| +0.30% | -0.71% | +29.05% | +30.33% | 4.25TCr | |
| -3.82% | -2.41% | -0.27% | +101.36% | 4.14TCr | |
| -2.13% | +1.07% | +7.51% | +50.31% | 3.13TCr | |
| -3.35% | -4.95% | -13.38% | -17.22% | 2.39TCr | |
| -1.24% | -7.47% | -37.90% | +311.13% | 2.22TCr | |
| Average | -4.23% | -2.63% | +36.66% | +144.16% | 4.29TCr | |
| Weighted average by Cap. | -4.86% | -1.88% | +43.05% | +136.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3L 4L 4L 4L 6L 4.13Cr 6L 42.62L 16.67L 2.1Cr 16L 15.65L 6.74Cr | 8L 10L 9L 8L 14.12L 9.61Cr 14.26L 99.2L 38.8L 4.88Cr 37.24L 36.43L 16Cr |
| Net income | -4.21Cr -5.57Cr -4.97Cr -4.64Cr -7.93Cr -539.26Cr -8.01Cr -56Cr -22Cr -274.03Cr -21Cr -20Cr -881.28Cr | -7.1Cr -9.38Cr -8.38Cr -7.82Cr -13Cr -908.81Cr -13Cr -94Cr -37Cr -461.81Cr -35Cr -34Cr -1.49TCr |
| Net Debt | -13Cr -18Cr -16Cr -15Cr -25Cr -1.7TCr -25Cr -175.91Cr -69Cr -865.56Cr -66Cr -65Cr -2.78TCr | -17Cr -23Cr -21Cr -19Cr -33Cr -2.23TCr -33Cr -230.02Cr -90Cr -1.13TCr -86Cr -84Cr -3.64TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
